Atorvastatin Oral Suspension
Atorvastatin is an oral liquid medicine used to lower cholesterol.
Atorvastatin Oral Suspension is indicated for:
Hypercholesterolaemia
Atorvastatin Oral Suspension is indicated as an adjunct to diet for reduction of elevated total cholesterol (total-C), LDL-cholesterol (LDL-C), apolipoprotein B, and triglycerides in adults, adolescents and children aged 10 years or older with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (Corresponding to Types IIa and IIb of the Fredrickson classification) when response to diet and other nonpharmacological measures is inadequate.
Atorvastatin Oral Suspension is also indicated to reduce total-C and LDL-C in adults with homozygous familial hypercholesterolaemia as an adjunct to other lipid-lowering treatments (e.g. LDL apheresis) or if such treatments are unavailable.
Prevention of cardiovascular disease
Prevention of cardiovascular events in adult patients estimated to have a high risk for a first cardiovascular event (see section 5.1), as an adjunct to correction of other risk factors.
Summary of Product Characteristics
Read this summary of product characteristics for further information about Atorvastatin Oral Suspension. Click below to navigate to the EMC.
Patient Information Leaflet
Read this patient information leaflet about Atorvastatin Oral Suspension, what it’s used for and possible side effects. Click below to navigate to the EMC.
Atorvastatin Oral Suspension
| Click here for Audio Version | |
| Flavour | Orange |
| Storage Conditions | Keep the bottle in the outer carton in order to protect from light. Do not freeze. Unopened bottle: Do not store above 25°C. After first opening the bottle: Do not store above 25°C. |
| Sucrose Free | |
| Shelf Life (Closed Bottle/Open Bottle) | 3 years / 60 days |
| PIP Code | 1256031 |
| EAN Code | 5016119000928 |
| Sodium Levels | Essentially sodium-free |
| Ethanol Concentration | None |
Downloads
Adverse Events
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk
Adverse events should also be reported to Rosemont at 0113 244 1400 or pharmacovigilance@rosemontpharma.com.
Contact us
For further product information and pricing please use the form below and a member of the team will be in touch
Stay updated via our App
A new Rosemont Pharmaceuticals App for Healthcare Professionals is launching soon.
Related Products
